Brief: Obseva: Positive Results From Uterine Fibroids Phase 3 Study Of Linzagolix
09/12/2019 06:08
Dec 9 (Reuters) - Obseva SA OBSN.S :
* OBSEVA ANNOUNCES POSITIVE RESULTS FROM UTERINE FIBROIDS
PHASE 3
STUDY (PRIMROSE 2) OF LINZAGOLIX
* PHASE 3 TRIAL (PRIMROSE 2) MET PRIMARY AND SECONDARY
EFFICACY
ENDPOINTS
Source text for Eikon: ID:nNDL9ZhBQV
Further company coverage: OBSN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary